Literature DB >> 9106777

Ion transport systems in the uptake of 99Tcm-tetrofosmin, 99Tcm-MIBI and 201Tl in a tumour cell line.

A S Arbab1, K Koizumi, K Toyama, T Arai, T Araki.   

Abstract

The kinetics, intracellular distribution and effects of ion transport inhibitors on the uptake of 99Tcm-tetrofosmin, 99Tcm-methoxyisobutyl isonitrile (99Tcm-MIBI) and 201Tl were investigated in a tumour cell line. Both uptake and washout of the tracers were measured at specific intervals. Cells were treated with ouabain, dimethyl amiloride (DMA) and bumetanide to observe the effects on uptake, while carbonyl cyanide m-chlorophenylhydrazone (CCCP) was used to study the release of the tracers. The tracers showed similar uptake and washout kinetics. Ouabain inhibited 55-67% of 201Tl, 16-22% of 99Tcm-tetrofosmin and 8-14% of 99Tcm-MIBI. DMA inhibited the uptake of both 99Tcm-tetrofosmin (30%) and 99Tcm-MIBI (21%). Bumetanide stimulated the uptake of 99Tcm-tetrofosmin and 99Tcm-MIBI but inhibited that of 201Tl (37%). When cells were pretreated with various combinations of these ion transport inhibitors, the uptake of 201Tl was related to Na+,K+ pump, Na+,K+, 2Cl- co-transport systems, whereas the uptake of both 99Tcm-tetrofosmin and 99Tcm-MIBI was related to the Na+,K+ pump, Na+/H+ antiport systems. Addition of CCCP released 55% and 90% of accumulated 99Tcm-tetrofosmin and 99Tcm-MIBI respectively, indicating that the percentage released was related to mitochondrial uptake.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9106777     DOI: 10.1097/00006231-199703000-00007

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  5 in total

1.  To use MIBI or not to use MIBI? That is the question when assessing tumour cells.

Authors:  Jean-Luc Moretti; Nathalie Hauet; Meltem Caglar; Olivier Rebillard; Zeynep Burak
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-07       Impact factor: 9.236

2.  Proof of concept for low-dose molecular breast imaging with a dual-head CZT gamma camera. Part II. Evaluation in patients.

Authors:  Carrie B Hruska; Amanda L Weinmann; Christina M Tello Skjerseth; Eric M Wagenaar; Amy L Conners; Cindy L Tortorelli; Robert W Maxwell; Deborah J Rhodes; Michael K O'Connor
Journal:  Med Phys       Date:  2012-06       Impact factor: 4.071

Review 3.  Use of tomographic nuclear medicine procedures, SPECT and pinhole SPECT, with cationic lipophilic radiotracers for the evaluation of axillary lymph node status in breast cancer patients.

Authors:  Giuseppe Madeddu; Angela Spanu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-04-15       Impact factor: 9.236

4.  99mTc-MIBI pinhole SPECT in primary hyperparathyroidism: comparison with conventional SPECT, planar scintigraphy and ultrasonography.

Authors:  Thomas Carlier; Aurore Oudoux; Eric Mirallié; Alain Seret; Isabelle Daumy; Christophe Leux; Caroline Bodet-Milin; Françoise Kraeber-Bodéré; Catherine Ansquer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10-25       Impact factor: 9.236

5.  The role of molecular breast imaging in predicting complete tumor response to treatment and residual tumor extent following neoadjuvant therapy.

Authors:  Susanna Nuvoli; Sarah Galassi; Ilaria Gelo; Gaia Rocchitta; Alessandro Fancellu; Pier Andrea Serra; Giuseppe Madeddu; Angela Spanu
Journal:  Oncol Rep       Date:  2018-03-06       Impact factor: 3.906

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.